Molecular Therapy
Volume 25, Issue 12, 6 December 2017, Pages 2620-2634
Original ArticleOncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Under a Creative Commons license
open access
Keywords
oncolytic parvovirus
glioblastoma
clinical trial
tumor microenvironment
Cited by (0)
- 15
These authors contributed equally to this work.
- 16
These authors contributed equally to this work.
- 17
These authors contributed equally to this work.
- 18
Present address: Department of Neurosurgery, Klinikum Darmstadt, Grafenstraße 9, 64283 Darmstadt, Germany
- 19
Present address: Charité Center Neurology, Neurosurgery and Psychiatry CC15, Campus Charité Mitte, Charitéplatz 1/Virchowweg 15, 10117 Berlin, Germany
- 20
Deceased November 11, 2016
© 2017 The Author(s).